PŘEHLEDOVÉ ČLÁNKY / REVIEW ARTICLES Antigeny buněčné stěny hub – úskalí jejich interpretace | 99 / Anest intenziv Med. 2026;37(2):94-100 / ANESTEZIOLOGIE A INTENZIVNÍ MEDICÍNA www.aimjournal.cz of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol. 2008;57(Pt 3):287-95. doi: 10.1099/jmm.0.47479-0. 10. Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55(4):521-6. doi: 10.1093/cid/cis456. 11. White SK, Schmidt RL, Walker BS, Hanson KE. (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people. Cochrane Database Syst Rev. 2020;7(7):CD009833. doi: 10.1002/14651858.CD009833.pub2. 12. White SK, Walker BS, Hanson KE, Schmidt RL. Diagnostic accuracy of β-d-glucan (Fungitell) testing among patients with hematologic malignancies or solid organ tumors: A systematic review and meta-analysis. Am J Clin Pathol. 2019;151(3):275-85. doi: 10.1093/ ajcp/aqy135. 13. Ullah N, Muccio M, Magnasco L, Sepulcri C, Giacobbe DR, Vena A, et al. Species-specific sensitivity and levels of beta-D-Glucan for the diagnosis of candidemia-A systematic review and meta-analysis. J Fungi (Basel). 2025;11(2):149. doi: 10.3390/jof11020149. 14. Rouzé A, Estella Á, Timsit J-F. Is (1,3)-β-D-glucan useless to guide antifungal therapy in ICU? Intensive Care Med. 2022;48(7):930-2. doi: 10.1007/s00134-022-06766-2. 15. Bloos F, Held J, Kluge S, Simon P, Kogelmann K, de Heer G, et al. (1→3)-β-D-Glucanguided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. Intensive Care Med. 2022;48(7):865-75. doi: 10.1007/s00134-022-06733-x. 16. Cornely OA, Sprute R, Bassetti M, Chen SC-A, Groll AH, Kurzai O, et al. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis. 2025;25(5):e280-93. doi: 10.1016/S1473-3099(24)00749-7. 17. Martin-Loeches I, Antonelli M, Cuenca-Estrella M, Dimopoulos G, Einav S, De Waele JJ, et al. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019;45(6):789-805. doi: 10.1007/s00134-019-05599-w. 18. Kritikos A, Poissy J, Croxatto A, Bochud P-Y, Pagani J-L, Lamoth F. Impact of the betaglucan test on management of intensive care unit patients at risk for invasive candidiasis. J Clin Microbiol. 2020;58(6). doi: 10.1128/jcm.01996-19. 19. Leroy O, Bailly S, Gangneux J-P, Mira J-P, Devos P, Dupont H, et al. Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study. Ann Intensive Care. 2016;6(1):2. doi: 10.1186/s13613-015-0103-7. 20. Furfaro E, Giacobbe DR, Del Bono V, Signori A, Guolo F, Minetto P, et al. Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies. Mycoses. 2018;61(9):650-5. doi: 10.1111/ myc.12787. 21. Lahmer T, Rasch S, Schnappauf C, Beitz A, Schmid RM, Huber W. Comparison of serum galactomannan and 1,3-beta-D-glucan determination for early detection of invasive pulmonary aspergillosis in critically ill patients with hematological malignancies and septic shock. Mycopathologia. 2016;181(7–8):505-11. doi: 10.1007/s11046-016-0011-x. 22. Pazos C, Pontón J, Del Palacio A. Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol. 2005;43(1):299-305. doi: 10.1128/JCM.43.1.299-305.2005. 23. Huang Q-Y, Li P-C, Yue J-R. Diagnostic performance of serum galactomannan and β-D-glucan for invasive aspergillosis in suspected patients: A meta-analysis. Medicine (Baltimore). 2024;103(5):e37067. doi: 10.1097/MD.0000000000037067. 24. Kolbrink B, Scheikholeslami-Sabzewari J, Borzikowsky C, von Samson-Himmelstjerna FA, Ullmann AJ, Kunzendorf U, et al. Evolving epidemiology of pneumocystis pneumonia: Findings from a longitudinal population-based study and a retrospective multi-center study in Germany. Lancet Reg Health Eur. 2022;18(100400):100400. doi: 10.1016/j. lanepe.2022.100400. 25. Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007;5(4):298-308. doi: 10.1038/nrmicro1621. 26. Damiani C, Le Gal S, Da Costa C, Virmaux M, Nevez G, Totet A. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1->3)-β-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol. 2013;51(10):3380-8. doi: 10.1128/JCM.01554-13. 27. Prosty C, Luo OD, Khalaf R, Del Corpo O, McDonald EG, Lee TC. Diagnostic test accuracy of the Fungitell serum (1→3)-β-D-glucan assay for the diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2025;31(4):542-50. doi: 10.1016/j.cmi.2024.11.004. 28. Costa J-M, Botterel F, Cabaret O, Foulet F, Cordonnier C, Bretagne S. Association between circulating DNA, serum (1→3)-β-D-glucan, and pulmonary fungal burden in Pneumocystis pneumonia. Clin Infect Dis. 2012;55(2):e5-8. doi: 10.1093/cid/cis412. 29. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140(5):1204-9. doi: 10.1164/ajrccm/140.5.1204. 30. Damiani C, Demey B, Pauc C, Le Govic Y, Totet A. A negative (1,3)-β-D-glucan result alone is not sufficient to rule out a diagnosis of Pneumocystis pneumonia in patients with hematological malignancies. Front Microbiol. 2021;12:713265. doi: 10.3389/ fmicb.2021.713265. 31. Mikulska M, Ullah N, Magnasco L, Codda G, Bartalucci C, Miletich F, et al. Lower (1,3)-betad-glucan sensitivity and in vitro levels in Candida auris and Candida parapsilosis strains. Clin Microbiol Infect. 2024;30(6):822-7. doi: 10.1016/j.cmi.2024.02.012. 32. León C, Ruiz-Santana S, Saavedra P, Castro C, Loza A, Zakariya I, et al. Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Crit Care. 2016;20(1):149. doi: 10.1186/s13054016-1324-3. 33. Goudjil S, Chazal C, Moreau F, Leke A, Kongolo G, Chouaki T. Blood product transfusions are associated with an increase in serum (1-3)-beta-d-glucan in infants during the initial hospitalization in neonatal intensive care unit (NICU). J Matern Fetal Neonatal Med. 2017;30(8):933-7. doi: 10.1080/14767058.2016.1191064. 34. Nagasawa K, Yano T, Kitabayashi G, Morimoto H, Yamada Y, Ohata A, et al. Experimental proof of contamination of blood components by (1→3)-beta-D-glucan caused by filtration with cellulose filters in the manufacturing process. J Artif Organs. 2003;6(1):49-54. doi: 10.1007/s100470300008. 35. Hammarström H, Kondori N, Friman V, Wennerås C. How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors. Eur J Clin Microbiol Infect Dis. 2015;34(5):917-25. doi: 10.1007/s10096-014-2302-9. 36. Duffner U, Abdel-Mageed A, Dahl K, Fogg G, Hester J. Serum (1→3)-β-D-glucan levels (Fungitell assay) is not useful as a screening test for recipients of an allogeneic HSCT while on immunoglobulin replacement. Bone Marrow Transplant. 2012;47(1):151-2. doi: 10.1038/bmt.2011.24. 37. Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-β-D-Glucan contamination of common antimicrobials. J Antimicrob Chemother. 2016;71(4):913-5. doi: 10.1093/jac/dkv419. 38. Ito S, Ashizawa M, Sasaki R, Ikeda T, Toda Y, Mashima K, et al. False-positive elevation of 1,3-beta-D-glucan caused by continuous administration of penicillin G. J Infect Chemother. 2018;24(10):812-4. doi: 10.1016/j.jiac.2018.06.008. 39. Mennink-Kersten MASH, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis. 2008;46(12):1930-1. doi: 10.1086/588563. 40. Held J, Kohlberger I, Rappold E, Busse Grawitz A, Häcker G. Comparison of (1→3)-β-Dglucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia. J Clin Microbiol. 2013;51(4):1158-64. doi: 10.1128/JCM.02473-12. 41. Albert O, Toubas D, Strady C, Cousson J, Delmas C, Vernet V, et al. Reactivity of (1→3)-β-d-glucan assay in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis. 2011;30(11):1453-60. doi: 10.1007/s10096-011-1244-8. 42. Racil Z, Kocmanova I, Toskova M, Winterova J, Lengerova M, Timilsina S, et al. Reactivity of the 1,3-β-D-glucan assay during bacteraemia: limited evidence from a prospective study: 1,3-Β-D-glucan and bacteraemia. Mycoses. 2013;56(2):101-4. doi: 10.1111/j.14390507.2012.02210.x. 43. Furfaro E, Mikulska M, Del Bono V, Guolo F, Minetto P, Gobbi M, et al. Bloodstream infections are an improbable cause of positive serum (1,3)-β-D-glucan in hematology patients. Clin Vaccine Immunol. 2014;21(9):1357-9. doi: 10.1128/CVI.00214-14. 44. Sawai T, Nakao T, Yamaguchi S, Yoshioka S, Matsuo N, Suyama N, et al. Detection of high serum levels of β-D-Glucan in disseminated nocardial infection: a case report. BMC Infect Dis. 2017;17(1):272. doi: 10.1186/s12879-017-2370-4. 45. Shah J, Dutta U, Rudramurthy S, Chakrabarti A, Sinha SK, Sharma V, et al. Colonic mucosa-associated candida assessed by biopsy culture is associated with disease severity in ulcerative colitis: A prospective study. J Dig Dis. 2019;20(12):642-8. doi: 10.1111/17512980.12825. 46. Leelahavanichkul A, Worasilchai N, Wannalerdsakun S, Jutivorakool K, Somparn P, Issara-Amphorn J, et al. Gastrointestinal leakage detected by serum (1→3)-β-D-glucan in mouse models and a pilot study in patients with sepsis. Shock. 2016;46(5):506-18. doi: 10.1097/SHK.0000000000000645. 47. Zhai B, Ola M, Rolling T, Tosini NL, Joshowitz S, Littmann ER, et al. High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis. Nat Med. 2020;26(1):59-64. doi: 10.1038/s41591-019-0709-7. 48. Samonis G, Kofteridis DP, Maraki S, Alegakis D, Mantadakis E, Papadakis JA, et al. Levofloxacin and moxifloxacin increase human gut colonization by Candida species. Antimicrob Agents Chemother. 2005;49(12):5189. doi: 10.1128/AAC.49.12.5189.2005. 49. Yang A-M, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017;127(7):2829-41. doi: 10.1172/JCI90562. 50. Szyszkowitz A, Zurl C, Herzeg A, Berger A, Gemes G, Mitteregger M, et al. Serum 1,3-betaD-Glucan values during and after laparoscopic and open intestinal surgery. Open Forum Infect Dis. 2018;5(12):ofy296. doi: 10.1093/ofid/ofy296. 51. Egger M, Horvath A, Prüller F, Fickert P, Finkelman M, Kriegl L, et al. Fungal translocation measured by serum 1,3-β-D-glucan correlates with severity and outcome of liver cirrhosis-A pilot study. Liver Int. 2023;43(9):1975-83. doi: 10.1111/liv.15648. 52. Kanda H, Kubo K, Hamasaki K, Kanda Y, Nakao A, Kitamura T, et al. Influence of various hemodialysis membranes on the plasma (1→3)-beta-D-glucan level. Kidney Int. 2001;60(1):319-23. doi: 10.1046/j.1523-1755.2001.00802.x. 53. Wong J, Zhang Y, Swift O, Finkelman M, Patidar A, Ramanarayanan S, et al. Beta-glucans
RkJQdWJsaXNoZXIy NDA4Mjc=